Hepatitis B and C Seroprevalence in Leprosy Patients

Yıl 2015, Cilt: 5 Sayı: 3, 114 - 118, 06.02.2016

Türkkan Kaygusuz Müge Özgüler , Leyla Güngör Çiğdem Papila

https://doi.org/10.5799/ahinjs.02.2015.03.0188

Cited By: 1

Öz

Objective: Leprosy is a contagious chronic granulomatous disease and commonly affects the eyes and the internal organs. Leprosy can be classified according to the level of immune response. Leprosy is a disease that is associated with defects in cellular immunity. This is why we have investigated the leprosy patients that were referred to our hospital for chronic hepatitis B and C co-infections. Methods: Fifty patients who were treated in the leprosy unit of Elazığ Research and Training hospital between the dates of June-December 2011 were enrolled to this descriptive study. Macro ELISA assay was performed for Hepatitis B,C and HIV.

Results: Fifty patients who were treated in the leprosy unit of our hospital participated in the study. A total of 8% HBsAg presence was noted. A total of 16 Anti HCV presence was noted in the patient group. Anti HCV positivity was determined at seven of 14 patients with tuberculoid form leprosy (50%) and nine of 33 lepromatous leprosy form (27,2%).

Conclusion: In conclusion, leprosy patients, especially lepromatous leprosy group, are immunologically vulnerable to HBV and HCV co-infections. Thus, physicians should be aware of HBV coinfections in these patients and education should be given to patients to increase their knowledge regarding risky situations for transmission of the disease. J Microbiol Infect Dis 2015;5(3): 114-118

Key words: Leprosy, Cellulary Immunity, Seroprevalance, Hepatitis B, Hepatitis C

Anahtar Kelimeler

-

Kaynakça

• Altıparmak E., Koçak M., Kundakçı N. et al. Prevalance of hepatitis
• B and hepatitis C infection in Leprosy patients. Turkish J Gastroenterology 1999; 10 (3):253-255.
• Chimenos KE, Pascual CM, Pinol DC, Vinals IH, Rodríguez de
• RCME, López LJ. Lepromatous leprosy: a review and case report. Med Oral Patol Oral Cir Bucal 2006; 11 (6):474-479.
• World Health Organization. Weekly epidemiological record,
• World Health Organization, 2011 (86);389-400.
• Turkey Directorate of Public Health. Leprosy (Hanseniyazis)
• http://www.thsm.gov.tr/upload/files/Lepra. (Turkish)
• Pungpapong S, Kim WR, Poterucha JJ. Natural history of
• hepatitis B virus infection: an update for clinicians. Mayo Clin
• Proc 2007; 82:967-75.
• European Centre for Disease Prevention and Control (ECDC).
• Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. September 2010. http://ecdc.europa.eu/en/publications/Publications/
• TER_100914_Hep_B_C%20_EU_neighbourhood.pdf 7. Tosun S. Hepatitis B vaccination and hepatitis vaccination results in our country, “Tabak F, Tosun S (eds). Viral Hepatitis”.Viral Hepatitis Prevention Society Publication, İstanbul Medical Press, İstanbul, 2013:413-439. (Turkish)
• Gülaçtı U,Üstün C, Arlıer R, Turan M. The Seroprevalence of Hepatitis B and C among Healthcare Persons in Elazig Harput State Hospital. Konuralp Med J 2013; 5 (3):5-8.(Turkish).
• Tözün N, Özdoğan O, Çakaloğlu Y, et al. A nationwide prevalence
• Sstudy and risk factors for hepatitis A, B, C and D infections in Turkey. The 61st Annual Meeting of AASLD: The Liver Meeting® 2010. October 29 November 2 2010, Boston USA, Poster No: 789, Hepatology 2010; 52:1-697A. http://www.tasl.org.tr/files/file/tasl.
• Balık İ, Tosun S, Tabak F, et al. Investigate the epidemiology
• of viral hepatitis with mobile team to in our country. (VHSD Bus Project), XI. Ulusal Viral Hepatitis congress, s.44, PS01-10, Antalya (2012).(Turkish).
• Ganem D, Prince AM. Hepatitis B virus infection – natural
• history and clinical consequences. N Engl J Med 2004;350:1118-1129.
• European Association for the Study of the Liver. EASL Clinical
• Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
• Rosa H, Costa AP, Ferraz ML, et al. Association between leprosy and hepatitis B infection. A survey in Goiania, central Brazil. Rev Inst Med Trop Sao Paulo 1992; 34:421-426.
• Motta AC, Pereira KJ, Tarquínio DC, Vieira MB, Miyake K,Foss NT. Leprosy reactions: co-infections as a possible risk factor. Clinics (Sao Paulo) 2012; 67 (10):1145-1148.
• Leitão C, Ueda D, de Moraes Braga AC, Boldt AB, MessiasReason
• IJ. Leprosy and hepatitis B coinfection in southern Brazil. Braz J Infect Dis 2014; 18(1):8-12.
• Ramos JM, Costa e Silva ÁM, Martins RM, et al. Prevalence of hepatitis B and C virus infection among leprosy patients in a leprosy-endemic region of central Brazil. Mem Inst Oswaldo Cruz 2011; 106:632-634.
• Yvonnet B, Vincelot P, Millan J, et al. Hepatitis B virus infection
• in lepromatous and tuberculoid patients from Senegal.Acta Leprol 1989; 7:63–6.
• Rego VP, Machado PR, Martins I, Trindade R, Paraná R.Type 1 reaction in leprosy: characteristics and association with hepatitis B and C viruses. Rev Soc Bras Med Trop 2007;40: 546-549.
• Nigam PK, Gupta GB, Khare A. Hepatic involvement and
• hepatitis B surface antigen (Hbs Ag) in leprosy. Indian J Dermatol
• Venereol Leprol 2003; 69 (1):32-4.
• Machado PR, Johnson WD, Glesby MJ. The role of human
• T cell lymphotrophic virus type 1, hepatitis B virus and hepatitis
• C virus coinfections in leprosy. Mem Inst Oswaldo Cruz2012; 107 (1):43-8.
• de Moraes Braga AC, Reason IJ, Maluf EC, Vieira ER. Leprosy
• and confinement due to leprosy show high association with hepatitis C in Southern Brazil. Acta Trop 2006; 97(1):88-93.